This transaction
Share transferThe voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
Development of new regenerative medicine methods using dedifferentiated fat cells Development of new regenerative medicine methods for animals Cell development, culture and management business
The impact of this share transfer on the Company’s consolidated results will be minor. If any matter requiring disclosure arises in the future, the Company will promptly announce it.
| Item | Details |
|---|---|
| Transaction name | Share transfer |
| Counterparty name | JOHN CHI CHONG FOU (ジョン・フー) |
| Name of the Subject Company | 株式会社ルミライズ |
| Business Description of the Subject Company | Development of new regenerative medicine methods using dedifferentiated fat cells Development of new regenerative medicine methods for animals Cell development, culture and management business |
| Location of the Subject Company | Ishibashi Building 506, 2-6-2 Shinkawa, Chuo-ku, Tokyo |
| Capital Stock of the Subject Company | ¥347 million |
| Date of Establishment of the Subject Company | 24 November 2021 |
| Net Sales of the Subject Company | ¥22.456 million (fiscal year ended April 2025) |
| Operating Profit of the Subject Company | Operating loss of ¥115.809 million (fiscal year ended April 2025) |
| Net Income of the Subject Company | Net loss of ¥118.183 million (fiscal year ended April 2025) |
| Net Assets of the Subject Company | Net assets of ¥163.561 million (fiscal year ended April 2025) |
| Acquisition price | Not disclosed at the request of the counterparty. |
| Number of shares acquired | 2,498 shares; number of voting rights: Not disclosed (voting rights ownership ratio: 35.99%) |
| Voting rights ownership percentage | Before 35.99％ → after 0％ |
| Impact on Business Performance | The impact of this share transfer on the Company’s consolidated results will be minor. If any matter requiring disclosure arises in the future, the Company will promptly announce it. |
| Date of board resolution | 26 May 2026 |
| Contract Date | 26 May 2026 |
| Execution Date / Effective Date | 28 May 2026 |
| Valuation methodology | Determined through discussions between the two companies |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The transfer is intended to optimize the business portfolio, promote the selection and concentration of management resources, and concentrate those resources on the financial services business and Web3-related business. It is also intended to eliminate future uncertainty in light of 株式会社ルミライズ’s performance falling below the initial plan, its operating loss trend, and future business risks.